Delivering Precise Immunotherapy With NGS in NSCLC
Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.
Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing (NGS) as a biomarker to predict response and progression-free survival rates in patients with nonsmall cell lung cancer (NSCLC) receiving pembrolizumab (Keytruda) monotherapy. The data were presented during the 2019 ASCO Annual Meeting.
How a circulating tumor DNA (ctDNA) NGS profile and serial and ctDNA NGS monitoring relates to patient response after pembrolizumab monotherapy in patients with NSCLC is unclear because of limited data. In the study, researchers gathered some of the missing data by collecting plasma at baseline, 9 weeks into treatment, and at 18 weeks into treatment. The NGS gene panel could detect 73 mutations in study patients.
